# POST-E1 T07 — Efficiency Reconciliation Acceptance

Status: **ACCEPTED / NO PRODUCT REMEDIATION**  
Governing phase: [#22](https://github.com/Habib1001-m/hakim/issues/22)  
T07 tracker: [#30](https://github.com/Habib1001-m/hakim/issues/30)  
Next slice: T08 Product-Value Decision

## Decision

`T07_FINAL_DECISION = EFFICIENCY_RECONCILED_NO_CHANGE`

T07 found no evidence-backed runtime/product defect that justifies changing the pinned Hakim behavior surface. The large E2 Run-002 elapsed debit remains preserved as real historical evidence, but it did not reproduce under the pre-frozen counterbalanced diagnostic replication.

No Hakim product-behavior change was made during T07.

## Pinned product surface

- Hakim behavior SHA: `3147203e0c0fadf0237b82cb9ea37f633bc4bab6`
- Claude plugin tree: `fe3ceb770d1b9b082dab802662bc396da8bc3044`
- T07 analyzer implementation SHA entering replication: `8bae8297ffa2c68e5cb7a6d5deb8a2dbfeec51eb`
- T07-D frozen replication-contract commit: `0eed50753db58676f5363f75c8cc25f030ba6c3b`

## T07-A — T06 efficiency ledger

T06 accepted evidence remains frozen in [`T06_ACCEPTANCE.md`](./T06_ACCEPTANCE.md).

The T06 phase median remained:

- elapsed overhead: `+3.21%` — PASS against the frozen `<=30%` gate;
- tool-call delta: `-29.17%` — PASS against the frozen `<=25%` gate;
- accepted scenario result: `3/3 TREATMENT_ADVANTAGE`;
- accepted functional/correctness regression: none observed.

The corrected E2 Run-002 `+73.15%` Treatment elapsed result remained explicit evidence debt rather than being normalized away.

## T07-B — Deterministic trace/timing analyzer

A zero-dependency analyzer was added at `scripts/analyze_post_e1_efficiency.mjs` with regression coverage in `tests/test_post_e1_efficiency_analyzer.mjs`.

Prove-first sequence:

- red contract/wiring head: `7c9f3f54843d1809911bbb9e68090505f8c0b228`;
- Public CI #461 / run `30224535072`: FAIL before analyzer implementation;
- implementation head: `8bae8297ffa2c68e5cb7a6d5deb8a2dbfeec51eb`;
- Public CI #462 / run `30224585351`: SUCCESS across the full gate plus Node 22/26 compatibility.

The analyzer reports directly observable trace timing and explicitly labels elapsed time outside observed tool-execution intervals as `UNATTRIBUTED`. It does not assign that residual time to Hakim, plugin hooks, model reasoning, provider latency, host scheduling, or any other mechanism without direct evidence.

## T07-C — Preserved T06 trace diagnosis

All six accepted T06 Control/Treatment evidence manifests passed integrity verification before analysis.

The E2 Run-002 pair showed:

- Control elapsed: `71.407s`;
- Treatment elapsed: `123.642s`;
- elapsed delta: `+73.15%`;
- Control observable tool-execution union: `1.599s`;
- Treatment observable tool-execution union: `3.044s`;
- observable tool-execution delta: `+1.445s`;
- Control residual/unattributed: `69.808s`;
- Treatment residual/unattributed: `120.598s`;
- residual delta: `+50.790s`.

Approximately 97% of the pair's absolute elapsed delta therefore sat outside directly observed tool-execution intervals. The trace could prove the timing difference, but not its cause.

The required T07-C classification was therefore:

`CAUSE_NOT_IDENTIFIABLE_FROM_CURRENT_EVIDENCE`

This rejected an unsupported `SYSTEMATIC_HAKIM_OVERHEAD_DEMONSTRATED` claim.

## T07-D — Counterbalanced E2 diagnostic replication

The replication was frozen before execution in [`T07_D_E2_REPLICATION.md`](./T07_D_E2_REPLICATION.md).

Controls:

- same pinned Hakim behavior/plugin tree;
- same corrected E2 task SHA-256 `2e15f709f1fe17e95b06732650fb25e1bf925bd556fff10a5c8d5d1c693a514a`;
- same corrected evaluator SHA-256 `11e93a9046733f27915e86f36a100a5f0e80b46a656889a92eee64ed359e03b7`;
- fresh Control/Treatment pair from one immutable seed;
- byte-identical execution configuration apart from Treatment activation;
- fixed counterbalanced order `CONTROL -> TREATMENT`;
- runner, checker, analyzer, contract, task, evaluator, and order sealed before execution.

### Replication result

| Metric | Control | Treatment | Treatment delta |
| --- | ---: | ---: | ---: |
| elapsed | `87.910s` | `87.917s` | `+0.008%` / `+7ms` |
| tool calls | `20` | `11` | `-45.00%` |
| task bookkeeping | `9` | `0` | `-100%` |
| observable tool-execution union | `2.006s` | `2.445s` | `+0.439s` |
| residual / unattributed | `85.904s` | `85.472s` | `-0.432s` |

Functional/runtime result:

- Control visible evaluator: PASS;
- Control hidden evaluator: PASS;
- Control representative baseline before first mutation: FAIL;
- Treatment visible evaluator: PASS;
- Treatment hidden evaluator: PASS;
- Treatment `hakim:hakim` before first mutation: PASS;
- Treatment representative baseline before first mutation: PASS;
- Treatment task bookkeeping: `0`;
- Treatment runtime checker: PASS.

The original large E2 debit therefore **did not replicate under opposite order**.

This does not prove that run order caused the original result. It demonstrates that the `+73.15%` wall-clock debit is not reproducible enough, from the current evidence, to treat it as a Hakim runtime characteristic or as a product defect requiring remediation.

## Why T07 stops here

The frozen replication rule said that a similarly large Treatment debit reappearing under counterbalanced order would justify considering further confirmatory evidence. It did not reappear.

A third replication at this point would shift from bounded diagnosis toward benchmark chasing without a demonstrated product defect.

A runtime/product optimization is therefore not justified. Changing the proven behavior surface to address an unreplicated latency outlier would create a new regression risk against the behaviors T06 established:

- skill-before-first-mutation;
- representative baseline-before-mutation;
- zero/default task bookkeeping on bounded work;
- evidence-sufficiency stopping behavior;
- domain-guard preservation;
- smallest sufficient/coherent/safe outcome semantics.

## Acceptance criteria

- [x] T06 efficiency truth preserved without rewriting the outlier.
- [x] Deterministic zero-dependency trace/timing analyzer implemented and regression-tested.
- [x] E2 outlier received an evidence-bounded classification.
- [x] Unsupported causal attribution explicitly rejected.
- [x] No efficiency optimization weakened the proven behavioral contract.
- [x] Diagnostic replication used a fresh sealed pair and the same pinned product behavior.
- [x] Large E2 elapsed debit did not reproduce under counterbalanced order.
- [x] No product/runtime remediation is justified by current evidence.
- [x] Final decision recorded as `EFFICIENCY_RECONCILED_NO_CHANGE`.

## Claim boundary

T07 does **not** establish universal speed, token, cost, ROI, or coding-quality superiority. It establishes only that the previously alarming E2 latency result did not reproduce in the bounded counterbalanced diagnostic replication and therefore does not justify product remediation on current evidence.

Stable release and external evaluator authorization remain separate decisions.
